As breast cancer ubiquitinated proteins (UPs) are considered potent antigens and have been characterized as short-lived proteins, Huang et al. delivered a DMXAA adjuvant UP-enriched therapeutic vaccine to 4T1/EPB breast cancer cells and elicited a robust CD8+ T-cell response. This evidence concerns the gene CD8A and breast carcinoma.